Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 12:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL) Clear all

Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

NCT02285062

View directory record Official record

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 22
States / cities: Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more

Source: ClinicalTrials.gov public record

Updated Jun 21, 2023 · Synced May 22, 2026, 12:11 AM EDT

Completed Phase 1 Interventional Results available

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

NCT02112526

View directory record Official record

Conditions: Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Interventions: Acalabrutinib; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years and older

Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • New York, New York + 2 more

Source: ClinicalTrials.gov public record

Updated Dec 19, 2024 · Synced May 22, 2026, 12:11 AM EDT

Terminated Phase 1 Interventional

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

NCT05144347

View directory record Official record

Conditions: Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions: XL114; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older

Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 4
States / cities: Tucson, Arizona • Indianapolis, Indiana • Pittsburgh, Pennsylvania + 1 more

Source: ClinicalTrials.gov public record

Updated Jul 10, 2023 · Synced May 22, 2026, 12:11 AM EDT

Recruiting Phase 1 Interventional

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

NCT06667687

View directory record Official record

Conditions: Non-Hodgkin's Lymphoma
Interventions: ABBV-291; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older

Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Huntersville, North Carolina • Eugene, Oregon • Austin, Texas + 2 more

Source: ClinicalTrials.gov public record

Updated Jan 25, 2026 · Synced May 22, 2026, 12:11 AM EDT